Bluewhale
Philadelphia, US · Founded 2022 · Delaware corporation · 1 known investors
Synecta develops cell-derived nanoparticles that activate immune cells for cell therapy manufacturing, improving potency and reducing costs. The product accelerates the delivery of CAR-engineered cell therapies with a simplified workflow.
Founders & leadership
PK
Peter KellerExecutive
Board
PM
EH
Elaine HeronBoard director
PC
Paula CannonBoard director
BM
Beate Mueller-TiemannBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$5M disclosed across 1 round · 2025
▶$5MraisedOct 2025 · 1 investors · BiotechnologyRule 506(b)
▶$5MraisedOct 2025 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Elaine HeronDirector
- Peter KellerExecutive Officer, Director
- Paul MeisterDirector
- Paula CannonDirector
- Beate Mueller-TiemannDirector
- Offering amount
- $15M
- Amount sold
- $5M
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Bluewhale do?
- Synecta develops cell-derived nanoparticles that activate immune cells for cell therapy manufacturing, improving potency and reducing costs. The product accelerates the delivery of CAR-engineered cell therapies with a simplified workflow.
- Who are Bluewhale's investors?
- Bluewhale's investors include Novalis LifeSciences.
- How much funding has Bluewhale raised?
- Bluewhale has disclosed $5M raised across 1 round.
- Where is Bluewhale headquartered?
- Bluewhale is headquartered in Philadelphia, US.